Mehmet Akin Tasyaran

Mehmet Akin Tasyaran

Auto-generated profile, based on publicly available information

Mehmet Akin Tasyaran

Department of Infectious Diseases and Clinical Microbiology, Yıldırım Beyazıt University School of Medicine, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Annals of Saudi Medicine
Verified
Journal Article
Open access
GYGul R. Yilmaz
Gul R. Yilmaz
MDMurat Dizbay
Murat Dizbay
TGTumer Guven
Tumer Guven
HPHusnu Pullukcu
Husnu Pullukcu
MTMeltem Tasbakan
Meltem Tasbakan
MTMehmet A. Tasyaran
Mehmet A. Tasyaran
Knowing risk factors for colistin resistance is important since colistin is the only remaining choice for the treatment of infections caused by multi-drug resistant microorganisms. Evaluate risk factors associated with infection by colistin-resistant microorganisms. Retrospective study. Tertiary healthcare centers. An e-mail including the title and purpose of the study was sent to 1500 infec.tious disease specialists via a scientific and social web portal named "infeksiyon dunyasi (infection world)". Demographic and clinical data was requested from respondents. Colistin-resistance. Eighteen infectious disease specialists from twelve tertiary care centers responded to the invitation data was collected on 165 patients, 56 cases (39.9%) and 109 (66.0%) age- and sex-matched controls. The colistin-resistant microorganisms isolated from cases were 29 Acinetobacter baumannii (51.8%), 18 Pseudomonas aeruginosa (32.1%) and 9 Klebsiella spp. Colistin, carbapenem, and quinolone use in the last three months were risk factors for colistin resistance in the univariate analysis. Previous quinolone use in the last three months (P=.003; RR:3.2; 95% Ci:1.5-6,7) and previous colistin use in the last three months (P=.001; RR: 3.6; 95% CI: 1.63-7.99) were significant risk factors in the multivariate analysis. Clinicians should limit the use of quinolones and remain aware of the possibility of resistance developing during colistin use. The lack of a heteroresistance analysis on the isolates. no data on use of a loading dose or the use of colistin in combination.

11 February 2019 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
FEFatma Eser
Fatma Eser
GYGül Ruhsar Yılmaz
Gül Ruhsar Yılmaz
RGRahmet Güner
Rahmet Güner
IHImran Hasanoglu
Imran Hasanoglu
FKFatma Yekta Ürkmez Korkmaz
Fatma Yekta Ürkmez Korkmaz
MTMehmet Akın Taşyaran
Mehmet Akın Taşyaran
This study aimed to evaluate the risk factors of patients colonized with carbapenem-resistant Enterobacteriaceae (CRE). The study was conducted between January 2010 and March 2016. The colonized group consisted of patients who had a CRE strain in their rectal swab cultures, whereas patients with negative rectal surveillance cultures for CRE who were concurrently hospitalized in the same units with the colonized group patients were included in the control group. The number of patients in the colonized and the control group was 71 and 120, respectively. Both groups were evaluated for demographic and healthcare-associated characteristics. Isolated microorganisms in rectal surveillance cultures for CRE were Klebsiella pneumoniae (75.5%), Escherichia coli (15.5%), Enterobacter cloacae (4.2%), Klebsiella oxytoca (1.4%), and Klebsiella terrigena (1.4%). The isolates were resistant to imipenem, meropenem, and ertapenem (52.1%, 73.2%, and 100%, respectively). In multivariate analysis, presence of decubitus, colistin usage, glycopeptide usage, and fluoroquinolone usage were found to be independent risk factors for CRE colonization. There was no significant difference between the two groups with regards to mortality (P = 0.070). These results are in agreement with the current literature. The findings of this study could be useful for improvement of infection control strategies related to CRE

1 August 2021 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
AKAyşe Kaya Kalem
Ayşe Kaya Kalem
RGRahmet Güner
Rahmet Güner
FEFatma Eser
Fatma Eser
IHImran Hasanoglu
Imran Hasanoglu
GYGül Ruhsar Yılmaz
Gül Ruhsar Yılmaz
MTMehmet Akın Taşyaran
Mehmet Akın Taşyaran

27 March 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
AÖaybegüm özşahin
aybegüm özşahin
ZTZeliha Kocak Tufan
Zeliha Kocak Tufan
RGRahmet Guner
Rahmet Guner
TBTuran Buzgan
Turan Buzgan
OTOsman Tecimel
Osman Tecimel
MTMehmet Akin Tasyaran
Mehmet Akin Tasyaran
With the prolongation of life expectancy and the developments in orthopedic surgery, noteworthy progress has been made in prosthetic joint surgery in recent years. Joint replacement provides pain relief, improves quality of life, and gives independence to individuals. Along with the advances in prosthetic surgery, prosthetic joint infection (PJI) is still the most feared complication of the procedure.

25 September 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
ABAyse Gulden Bekgoz
Ayse Gulden Bekgoz
RGRahmet Guner
Rahmet Guner
OKOrhan Kucuksahin
Orhan Kucuksahin
IHImran Hasanoglu
Imran Hasanoglu
AKAyşe Kaya Kalem
Ayşe Kaya Kalem
MTMehmet Akin Tasyaran
Mehmet Akin Tasyaran
Immunosuppressive drugs are increasingly used in the treatment of rheumatologic diseases to achieve disease remission, reduce the frequency of attacks, and prevent relapses. Since the late 1990s, advancements in molecular biology, immunology, and pharmaceutical technologies have led to various new treatment approaches for autoimmune-associated inflammatory diseases.

1 August 2021 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
AKAyşe Kaya Kalem
Ayşe Kaya Kalem
RGRahmet Güner
Rahmet Güner
FEFatma Eser
Fatma Eser
IHImran Hasanoglu
Imran Hasanoglu
GYGül Ruhsar Yılmaz
Gül Ruhsar Yılmaz
MTMehmet Akın Taşyaran
Mehmet Akın Taşyaran